Rosiglitazone treatment increases nitric oxide production in human peripheral skin: A controlled clinical trial in patients with type 2 diabetes mellitus

Journal of Diabetes and its Complications

Volumn 17, Issue 5, 2003, Pages 279-285

  Vinik, Aaron I ^a   Stansberry, Kevin B ^a   Barlow, Patricia M ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Blood flow; Microvascular; Nitric oxide; Rosiglitazone; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; BIOLOGICAL MARKER; C PEPTIDE; NITRIC OXIDE; ROSIGLITAZONE;

ADULT; AMPEROMETRY; ARTICLE; BLOOD FLOW; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENDOTHELIUM CELL; FEMALE; HUMAN; INSULIN SYNTHESIS; LASER DOPPLER FLOWMETRY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGAN PERFUSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SKIN; STATISTICAL SIGNIFICANCE;

EID: 0042386047     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(03)00006-0     Document Type: Article

References (40)

1. Agrawal A., Chen H., Yan Y., Mather R., Albertini J.P., Valensi P., Hanefeld M. Rosiglitazone improves postprandial glycemia and markers of endothelial dysfunction in patients with type 2 diabetes. Diabetes. 51(Suppl. 2):2002;372-P.
2. Avogaro A., Piarulli F., Valerio A., Miola M., Calveri M., Pavan P., Vicini P., Cobelli C., Tiengo A., Calo L., Del Prato S. Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients. Diabetes. 46:1997;1040-1046.
3. Baron A.D. Insulin resistance and vascular function. Journal of Diabetic Complications. 16:2002;92-102.
4. Caballero A.E., Arora S., Saouaf R., Lim S.C., Smakowski P., Park J.Y., King G.L., LoGerfo F.W., Horton E.S., Veves A. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 48:1999;1856-1862.
5. Colberg S.R., Stansberry K.B., McNitt P.M., Vinik A.I. Chronic exercise is associated with enhanced cutaneous blood flow in type 2 diabetes. Journal of Diabetic Complications. 16:2002;139-145.
6. Facchini F.S., DoNascimento C., Reaven G.M., Yip J.W., Ni X.P., Humphreys M.H. Blood pressure, sodium intake, insulin resistance, and urinary nitrate excretion. Hypertension. 33:1999;1008-1012.
7. Farkas K., Sarman B., Jermendy G., Somogyi A. Endothelial nitric oxide in diabetes mellitus: too much or not enough? Diabetes, Nutrition & Metabolism. 13:2000;287-297.
8. Ghazzi M.N., Perez J.E., Antonucci T.K., Driscoll J.H., Huang S.M., Faja B.W., Whitcomb R.W. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes. 46:1997;433-439.
9. Goodfellow J., Ramsey M.W., Luddington L.A., Jones C.J., Coates P.A., Dunstan F., Lewis M.J., Owens D.R., Henderson A.H. Endothelium and inelastic arteries: an early marker of vascular dysfunction in non-insulin dependent diabetes. British Medical Journal. 312:1996;744-745.
10. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 106:2002;679-684.
11. Hoeldtke R.D., Bryner K.D., McNeill D.R., Hobbs G.R., Riggs J.E., Warehime S.S., Christie I., Ganser G., Van Dyke K. Nitrosative stress, uric acid, and peripheral nerve function in early type 1 diabetes. Diabetes. 51:2002;2817-2825.
12. Home P., Gubb J. Rosiglitazone evaluated for cardiac outcomes and regulation of glycemia in diabetes (RECORD): a long-term cardiovascular outcome study. Diabetes. 51(Suppl. 2):2002;. Abstract No. 2003.
13. Inzucchi S.E., Maggs D.G., Spollett G.R., Page S.L., Rife F.S., Walton V., Shulman G.I. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. New England Journal of Medicine. 338:1998;867-872.
14. Jaap A.J., Hammersley M.S., Shore A.C., Tooke J.E. Reduced microvascular hyperaemia in subjects at risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 37:1994;214-216.
15. Lee B.C., Shore A.C., Humphreys J.M., Lowe G.D., Rumley A., Clark P.M., Hattersley A.T., Tooke J.E. Skin microvascular vasodilatory capacity in offspring of two parents with type 2 diabetes. Diabetic Medicine. 18:2001;541-545.
16. Lin K.Y., Ito A., Asagami T., Tsao P.S., Adimoolam S., Kimoto M., Tsuji H., Reaven G.M., Cooke J.P. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 106:2002;987-992.
17. Maejima K., Nakano S., Himeno M., Tsuda S., Makiishi H., Ito T., Nakagawa A., Kigoshi T., Ishibashi T., Nishio M., Uchida K. Increased basal levels of plasma nitric oxide in type 2 diabetic subjects. Relationship to microvascular complications. Journal of Diabetic Complications. 15:2001;135-143.
18. McVeigh G.E., Brennan G.M., Johnston G.D., McDermott B.J., McGrath L.T., Henry W.R., Andrews J.W., Hayes J.R. Impaired endothelium-dependent and independent vasodilatation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 35:1992;771-776.
19. Miyazaki H., Matsuoka H., Cooke J.P., Usui M., Ueda S., Okuda S., Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 99:1999;1141-1146.
20. Mohanty P., Aljada A., Ghanim H., Hofmayer D., Tripathy D., Syed T., Dhindsa S., Dandona P. Evidence for a potent anti-inflammatory effect of rosiglitazone in obese diabetes patients. Diabetes. 51(Suppl. 2):2002;. 441-P.
21. Mohanty P., Aljada A., Ghanim H., Tripathy D., Syed T., Hofmeyer D., Dandona P. Rosiglitazone improves vascular reactivity, inhibits reactive oxygen species (ROS) generation, reduces p47phox subunit expression in mononuclear cells (MNC): Evidence of a potent anti-inflammatory effect. Diabetes. 50(Suppl. 1):2001;. 276-OR.
22. Morris S.J., Shore A.C., Tooke J.E. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia. 38:1995;1337-1344.
23. Natali A., Baldeweg S., Toschi E., Barbaro D., Capaldo B., Yudkin J., Ferranini E. Rosiglitazone directly improves endothelial function in type 2 diabetes patients. Diabetes. 51(Suppl. 2):2002;. 573-P.
24. Neugebauer S., Baba T., Watanabe T. Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes. Diabetes. 49:2000;500-503.
25. Shastry S., Dietz N.M., Halliwill J.R., Reed A.S., Joyner M.J. Effects of nitric oxide synthase inhibition on cutaneous vasodilation during body heating in humans. Journal of Applied Physiology. 85:1998;830-834.
26. Sidhu J., Cava D., Kaski J.C. The PPARγ agonist rosiglitazone reduces endothelial activation in non-diabetics with coronary disease. European Heart Journal. 23:2002;519.
27. Song J., Walsh M.F., Igwe R., Ram J.L., Barazi M., Dominguez L.J., Sowers J.R. Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production. Diabetes. 46:1997;659-664.
28. St John Sutton M., Rendell M., Dandona P., Dole J.F., Murphy K., Patwardhan R., Patel J., Freed M. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes mellitus. Diabetes Care. 25:2002;2053-2064.
29. Stansberry K.B., Peppard H.R., Babyak L.M., Popp G., McNitt P.M., Vinik A.I. Primary nociceptive afferents mediate the blood flow dysfunction in non-glabrous (hairy) skin of type 2 diabetes: a new model for the pathogenesis of microvascular dysfunction. Diabetes Care. 22:1999;1549-1554.
30. Stansberry K.B., Scanelli J.A., McNitt P.M., Vinik A.I. Nitric oxide production mediates neurogenic vasodilatation in human skin but is not impaired in type 2 diabetes. Diabetes. 49(Suppl. 1):2000;A33.
31. Stansberry K.B., Vinik A.I. Nitric oxide is impaired in impaired glucose tolerance (OGT) and first order relatives of patients with type 2 diabetes. Diabetes. 50:2001;A63-OR.
32. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., Holman R.R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. British Medical Journal. 321:2000;405-412.
33. Stuhlinger M.C., Abbasi F., Chu J.W., Lamendola C., McLaughlin T.L., Cooke J.P., Reaven G.M., Tsao P.S. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA, Journal of the American Medical Association. 287:2002;1420-1426.
34. Veves A., Akbari C.M., Primavera J., Donaghue V.M., Zacharoulis D., Chrzan J.S., DeGirolami U., LoGerfo F.W., Freeman R. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes. 47:1998;457-463.
35. Vinik A.I., Erbas T., Park T.S., Stansberry K.B., Scanelli J.A., Pittenger G.L. Dermal neurovascular dysfunction in type 2 diabetes. Diabetes Care. 24:2001;1468-1475.
36. Wakino S., Law R.E., Hsueh W.A. Vascular protective effects by activation of nuclear receptor PPARgamma. Journal of Diabetic Complications. 16:2002;46-49.
37. Walker A.B., Chattington P.D., Buckingham R.E., Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes. 48:1999;1448-1453.
38. Watts G.F., O'Brien S.F., Silvester W., Miller J.A. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clinical Science (London). 91:1996;567-573.
39. Williams S.B., Cusco J.A., Roddy M.A., Johnstone M.T., Creager M.A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. Journal of the American College of Cardiology. 27:1996;567-574.
40. World Health Organization. (1980). Diabetes mellitus: report of a WHO study group (Tech. Rep. Series No. 646). Geneva: World Health Organization.